Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

103.93 19.03 −15.48%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
25.79 13.66 17.47 37.25 14.11 44.49 0.00 0.00 50.50 0.00
Piotroski F-Score
5 9 8 4 5 7 3 3 7 2
P/S ratio
5.77 5.97 5.95 11.43 12.76 21.74 13.06 13.83 8.70 8.71
Altman Z-Score
3.46 4.31 3.41 4.14 5.77 8.55 2.67 5.48 5.91 (0.12)
P/FCF ratio
12.51 12.95 13.21 28.87 18.98 107.68 0.00 0.00 20.77 0.00
Altman Z″-Score (non-manufacturers)
3.02 5.60 3.93 3.50 6.54 0.88 1.23 0.52 3.26 (4.49)
Beneish M-Score
(2.59) (2.33) (2.74) (0.57) 0.26 (1.25) (1.56) (1.35) (0.87) (4.61)
P/Operating CF
36.82 33.98 48.19 91.50 68.54 114.25 (96.11) 200.81 17.98 (81.08)
P/B ratio
165.22 16.67 58.86 44.43 28.71 38.51 27.89 8.44 13.23 0.00
EV/Sales
7.72 6.90 7.39 13.16 13.06 23.32 12.96 12.33 7.86 8.79
EV/EBITDA
19.20 11.13 14.47 26.64 20.33 38.40 0.00 0.00 29.41 0.00
EV/FCF
16.72 14.96 16.42 33.25 19.43 115.50 (28.39) (34.58) 18.75 (24.10)
Current Ratio
4.66 7.80 6.64 5.65 7.91 1.32 6.35 2.86 3.89 4.70
Net Debt/EBITDA
3.56 1.45 2.75 3.51 0.48 0.18 0.29 3.33 (3.15) (0.17)
Debt/Equity
43.89 4.14 17.89 8.87 4.45 2.63 4.39 0.51 0.97 (6.67)
ROE
153.59% 198.42% 222.07% 110.23% 231.44% 106.33% (42.41%) (35.14%) 71.60% (1,958.98%)
ROA
13.81% 23.39% 15.75% 13.72% 47.82% 22.53% (14.36%) (16.73%) 16.12% (46.48%)
ROIC
14.31% 27.06% 16.92% 12.73% 51.83% 50.02% (57.81%) (208.92%) 0.00% 0.00%
Return on Tangible Assets
43.39% 43.48% 39.72% 29.56% 49.24% 89.66% (15.41%) (28.09%) 16.46% (49.96%)
Average Days of Receivables
115.33 110.89 103.09 127.77 74.90 133.30 110.70 72.12 25.52 39.02
Earnings Yield
3.88% 7.32% 5.72% 2.68% 7.09% 2.25% (2.82%) (3.79%) 1.98% (8.11%)
Free Cash Flow Yield
7.99% 7.72% 7.57% 3.46% 5.27% 0.93% (3.50%) (2.58%) 4.82% (4.19%)
Free Cash Flow per Share
5.38 3.69 2.83 1.91 2.12 0.40 (0.62) (0.38) 0.97 (0.42)
Book value per Share
0.41 2.87 0.64 1.24 1.40 1.11 0.64 1.73 1.53 (0.25)
Free Cash Flow
644.59 468.37 373.28 261.31 297.98 54.03 (89.46) (54.16) 132.70 (53.52)
EV/EBIT
22.98 12.70 18.15 32.47 20.99 43.26 0.00 0.00 30.73 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026